Belinostat

Belinostat is a novel hydroxamate-type inhibitor of histone deacetylase activity. It inhibits HDAC activity in HeLa cell extracts with an IC50 of 27 nM. Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC50s in the range 0.2-3.4 µM as determined by a clonogenic assay and induces apoptosis. This hdac inhibitor is currently under phase I/II testing in lymphoma, ovarian cancer and other solid tumors.

Synonyms: Belinostat; PXD101; PX105684; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide
Technical Data: Molecular Weight - 318.35; Molecular formula - C15H14N2O4S; CAS No - 414864-00-9

Ordering Information: Product Number - EC-000.2286
Price and Availability: Inquire
This product is also available to buy in bulk quantities.

Special offer
We are pleased to offer you set of eight HDAC inhibitors* at the best current market price:
$600/8 inhibitors* x 10 mg
$1100/8 inhibitors* x 50 mg
$1450/8 inhibitors* x 100 mg
Shipping and handling costs: $150
Delivery time: 5-10 days by courier from stock.
This special sale is for limited time only
* - Suberoylanilide Hydroxamic Acid (SAHA); Entinostat (MS-275); Tacedinaline (CI-994); BML-210; M344; Mocetinostat (MGCD0103); PXD101; LBH-589.

References:
1. Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8.
2. Zain JM, et al. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol. 2010 Jun 10.
3. Ramalingam SS, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan;4(1):97-101.

Related service: collection of Histone Deacetylase Inhibitors.